NCT05292196

A Phase II Clinical Trial of TQC3721 Suspension for Inhalation

A Randomized, Double-blind, Placebo-parallel, Multicenter Phase II Trial of the Efficacy and Safety of TQC3721 Suspension for Inhalation in the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

TQC3721 suspension for inhalation is a PDE3/4 inhibitor developed by Chia Tai Tianqing Pharmaceutical Group Co., LTD., which can simultaneously achieve bronchial smooth muscle relaxation and anti-inflammatory effects. This is a randomized, double-blind, placebo-parallel, phase II trial of the efficacy and safety of inhaled TQC3721 suspension/placebo at different doses in patients with moderate to severe chronic obstructive pulmonary disease. Objective To evaluate the efficacy, safety and tolerability of TQC3721 inhalation suspension in the treatment of moderate to severe Chronic Obstructive Pulmonary Disease (COPD).

Conditions

• Chronic Obstructive Pulmonary Disease (COPD)

Interventions

Type	Name	Description
DRUG	TQC3721 suspension for inhalation	TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
DRUG	TQC3721 suspension placebo for inhalation	TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor

Timeline

• Start date: 2022-05-20
• Primary completion: 2023-01-11
• Completion: 2023-12-05
• First posted: 2022-03-23
• Last updated: 2025-04-20

Locations

11 sites across 1 country: China